We were able to model the impact of risk stratifying patients with advanced fibrosis in a wide spectrum of NAFLD patients, including the important subset with normal ALT, and show that the ranking of strategies was unchanged, although the cost of risk stratifying strategies is lower in patients with normal liver enzymes. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.